Amarin Corporation plc (AMRN) NASDAQ
14.55
+0.28(+1.96%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
14.55
+0.28(+1.96%)
Currency In USD
| Previous Close | 14.27 |
| Open | 14.34 |
| Day High | 14.71 |
| Day Low | 14.18 |
| 52-Week High | 20.9 |
| 52-Week Low | 10.85 |
| Volume | 31,802 |
| Average Volume | 71,574 |
| Market Cap | 300.93M |
| PE | -9.09 |
| EPS | -1.6 |
| Moving Average 50 Days | 14.69 |
| Moving Average 200 Days | 15.45 |
| Change | 0.28 |
Data not available
Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology
GlobeNewswire Inc.
Mar 02, 2026 1:00 PM GMT
Peer-reviewed paper indicates icosapent ethyl (IPE) was associated with fewer total hospitalizations and fewer days lost due to hospitalization and death, providing additional insights on the effects of IPE on patient-centered measures of total disea
This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease
GlobeNewswire Inc.
Feb 23, 2026 1:00 PM GMT
DUBLIN and BRIDGEWATER, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today issued a call to action for American Heart Month em
Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026
GlobeNewswire Inc.
Feb 11, 2026 1:00 PM GMT
DUBLIN and BRIDGEWATER, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report fourth quarter and full year 2025 financ